	US 11,692,023 B2
	Human zika virus antibodies and methods of use therefor
James E. Crowe, Jr., Nashville, TN (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on May 17, 2021, as Appl. No. 17/321,732.
Application 17/321,732 is a continuation of application No. 16/346,709, granted, now 11,021,533, previously published as PCT/US2017/059531, filed on Nov. 1, 2017.
Claims priority of provisional application 62/416,260, filed on Nov. 2, 2016.
Prior Publication US 2021/0347864 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 31/14 (2006.01); A61K 39/42 (2006.01); C07K 16/10 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/1081 (2013.01) [A61K 39/42 (2013.01); A61P 31/14 (2018.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/18 (2013.01); G01N 2333/185 (2013.01); Y02A 50/30 (2018.01)]

14 Claims

1. An isolated monoclonal antibody that specifically binds to Zika virus E protein, comprising heavy chain CDR sequences SEQ ID NO: 266; 267 and 268; and light chain CDR sequences SEQ ID NO:269; GAS; and SEQ ID NO:270; wherein the antibody comprises a mutagenized Fc variant sequence exhibiting reduced FcR interactions.